BIT News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

BI

AUM

$633.4M

Volume

343.54K

Yield

13.37%

Chart Earnings News About Dividends Insider Filings

Zacks Investment Ideas feature highlights: ARGT, IWM, BIT, NVIDIA, Alibaba and JD.comARGT, IWM, BIT, NVIDIA, Alibaba and JD.com are part of the Zacks Investment Ideas article.Zacks Investment Research · May 24, 2024

PDI: 100 Big Yield CEFs, REITs, MLPs - These 3 Worth ConsideringWe share updated data on over 100 big-yield opportunities, including CEFs, REITs, and MLPs. Learn more about PDI CEF and our recommendation.Seeking Alpha · Aug 31, 2023

Philogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic ProteinPhilogen enters into a Service and Supply Agreement with IBSA for the GMP Production of a Therapeutic ProteinGlobeNewswire Inc. · Jun 28, 2023

Philogen Announces Clinical Trial Collaboration with MSD The Phase II clinical trial investigates Philogen's immunocytokines (i) L19IL2 (ii) L19TNF, and (iii) Nidlegy™ in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in stage III and IV unresectable melanoma patients who previously failed treatment with checkpoint inhibitorsGlobeNewswire Inc. · Jun 1, 2023

Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New ZealandMumbai, India and Siena, Italy, 30th May 2023 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, “Sun Pharma”)) and Philogen S.p.A (BIT: PHIL) today announced that they have entered into a licensing agreement for commercializing Philogen’s specialty product, Nidlegy™ (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy™, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is being developed by Philogen for the treatment of melanoma and non-melanoma skin cancers.GlobeNewswire Inc. · May 30, 2023

Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital ZürichPhilogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital ZürichGlobeNewswire Inc. · May 25, 2023

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library TechnologyPhilogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library TechnologyGlobeNewswire Inc. · Mar 28, 2023

Cathie Wood Can't Get Enough of This Crypto StockCathie Wood is buying Coinbase stock like it's going out of style.The Motley Fool · Mar 7, 2023

Where Is Crypto Going Next? These 3 Tokens Offer a Glimpse of the FutureThis might be a crypto winter, but innovators in the industry are not hibernating.The Motley Fool · Mar 2, 2023

Beyond Bitcoin: 3 Tokens Changing the Crypto LandscapeUniswap, Polygon, and BitDAO are ahead of important transformational trends in the crypto industry.The Motley Fool · Jan 25, 2023

BI

BITBLACKROCK MULTI-SECTOR INCOME TRUST

BIT

Pay with—

Available Balance0.00

Your PositionYou don't own any BIT yet.

Related Tickers

Earnings

Dividends

Ex Nov 13

Amount$0.12

PaysOct 30

Last · Oct 15Monthly

Amount$0.12

Yield13.40%

Annual$1.49